S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:PNT

POINT Biopharma Global (PNT) Stock Forecast, Price & News

$9.41
+0.02 (+0.21%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$9.26
$9.65
50-Day Range
$6.78
$10.86
52-Week Range
$5.59
$11.13
Volume
458,900 shs
Average Volume
630,465 shs
Market Capitalization
$994.45 million
P/E Ratio
11.20
Dividend Yield
N/A
Price Target
$15.71

POINT Biopharma Global MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
67.0% Upside
$15.71 Price Target
Short Interest
Bearish
9.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of POINT Biopharma Global in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.76) to ($0.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

341st out of 1,010 stocks

Pharmaceutical Preparations Industry

151st out of 494 stocks


PNT stock logo

About POINT Biopharma Global (NASDAQ:PNT) Stock

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

PNT Stock News Headlines

Why Your IRA Could Crash on June 16th
China will attack Taiwan as soon as June 16th, 2023. The stock market will crash at least 35% when China makes their move.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
POINT Biopharma Global (NASDAQ:PNT) Shares Down 3.4%
POINT Biopharma Global (NASDAQ:PNT) Trading 6.6% Higher
See More Headlines
Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

PNT Company Calendar

Last Earnings
3/27/2023
Today
5/29/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PNT
Fax
N/A
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.71
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+67.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$98.29 million
Pretax Margin
54.70%

Debt

Sales & Book Value

Annual Sales
$226.58 million
Cash Flow
$0.94 per share
Book Value
$4.68 per share

Miscellaneous

Free Float
85,920,000
Market Cap
$994.45 million
Optionable
Not Optionable
Beta
0.14

Key Executives

  • Mr. Allan Charles Silber (Age 72)
    Exec. Chairman
    Comp: $677.8k
  • Dr. Joe A. McCann Ph.D. (Age 44)
    CEO & Director
    Comp: $740.31k
  • Dr. Neil E. Fleshner FRCSC (Age 59)
    M.D., M.PH, Chief Medical Officer & Director
    Comp: $227.5k
  • Ms. Jessica D. Jensen M.P.H. (Age 41)
    MPH, Exec. VP of Clinical Devel.
    Comp: $541.59k
  • Mr. Bill Demers B.B.A. (Age 64)
    F.C.A., FCPA, Chief Financial Officer
  • Ms. Justyna Kelly M.Sc. (Age 37)
    Chief Operating Officer
  • Ms. Donna Husack B.A.
    VP of HR
  • Mr. Ari Shomair
    VP of Corp. Affairs & Chief of Staff
  • Dr. Myra Rosario Herle Ph.D.
    R.Ph., Exec. VP of Regulatory Affairs
  • Dr. Matthew P. Vincent J.D.
    Ph.D., Sr. VP of Bus. Devel.













PNT Stock - Frequently Asked Questions

Should I buy or sell POINT Biopharma Global stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PNT shares.
View PNT analyst ratings
or view top-rated stocks.

What is POINT Biopharma Global's stock price forecast for 2023?

8 Wall Street analysts have issued 12-month price objectives for POINT Biopharma Global's stock. Their PNT share price forecasts range from $11.00 to $22.00. On average, they anticipate the company's stock price to reach $15.71 in the next twelve months. This suggests a possible upside of 67.0% from the stock's current price.
View analysts price targets for PNT
or view top-rated stocks among Wall Street analysts.

How have PNT shares performed in 2023?

POINT Biopharma Global's stock was trading at $7.29 at the beginning of 2023. Since then, PNT stock has increased by 29.1% and is now trading at $9.41.
View the best growth stocks for 2023 here
.

When is POINT Biopharma Global's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our PNT earnings forecast
.

How were POINT Biopharma Global's earnings last quarter?

POINT Biopharma Global Inc. (NASDAQ:PNT) issued its earnings results on Monday, March, 27th. The company reported $1.53 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $1.79. The company earned $226.58 million during the quarter, compared to the consensus estimate of $260 million.

What ETFs hold POINT Biopharma Global's stock?
What is POINT Biopharma Global's stock symbol?

POINT Biopharma Global trades on the NASDAQ under the ticker symbol "PNT."

Who are POINT Biopharma Global's major shareholders?

POINT Biopharma Global's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (10.00%), BlackRock Inc. (5.19%), Great Point Partners LLC (3.20%), State Street Corp (2.95%), Rubric Capital Management LP (2.50%) and Geode Capital Management LLC (1.50%). Insiders that own company stock include Allan C Silber, Joe A Mccann, Jonathan R Goodman, Neil E Fleshner and Yael Margolin.
View institutional ownership trends
.

How do I buy shares of POINT Biopharma Global?

Shares of PNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is POINT Biopharma Global's stock price today?

One share of PNT stock can currently be purchased for approximately $9.41.

How much money does POINT Biopharma Global make?

POINT Biopharma Global (NASDAQ:PNT) has a market capitalization of $994.45 million and generates $226.58 million in revenue each year. The company earns $98.29 million in net income (profit) each year or $0.84 on an earnings per share basis.

How can I contact POINT Biopharma Global?

POINT Biopharma Global's mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The official website for the company is www.pointbiopharma.com. The company can be reached via phone at 64-7812-2417.

This page (NASDAQ:PNT) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -